CMA Media Release

16 February 2018

CMA welcomes new approval pathway as part of a world class regulatory regime

Mr Carl Gibson, ceo of Complementary Medicines Australia (CMA) said: "We applaud the continued implementation of the government agreed recommendations from the Medicines and Medical Devices Review (MMDR), including amendments to provide a new approval pathway for listing complementary medicines with higher therapeutic indications and health claims."

"CMA welcomes the passing in the Senate of the *Therapeutic Goods Amendment (2017 Measures No. 1) Bill 2017* and reiterates its support of the government's commitment to foster a regulatory environment that is supportive of innovation and competitiveness."

"The goal is to encourage and reward greater investment in research and development by industry and be an incentive to further expand the clinical research base for complementary medicines, enabling Australian companies to expand business opportunities," said Mr Gibson.

"Achieving an appropriate regulatory regime – one that is supportive of innovation but that doesn't undermine the current high standards for Australian complementary medicines – will assist the complementary medicines industry to bring innovative new products to both the Australian and global markets."

"The use of traditional and complementary medicines is growing worldwide. Consumers have been turning to traditional and complementary medicines as part of a proactive approach to healthcare, becoming more confident in self-selection and willing to take preventive measures to support their health."

"In a supportive business and regulatory environment, the Australian complementary medicines industry is one industry that has the ability to continue its rapid growth, to support local innovation-rich manufacturing, and Australian-based research and development," concluded Mr Gibson.

ENDS

For Media Interviews or Further Information Contact:
CMA, Chief Executive Carl Gibson +61 457 028 974